Legend Biotech Shareholders Approve 19.1M Share Equity Plan Increase and Ratify EY as Auditor
LEGN sits 17% above its 52-week low of $16.24.
Summary
Legend Biotech's 2026 AGM approved a 19.1 million share increase to its equity plan and ratified Ernst & Young as independent auditor for fiscal 2026.
Key Events · Corporate Governance and Compliance · LEGN
-
Equity Plan Increase Approved
Shareholders approved an amendment to the 2020 Restricted Shares Plan increasing the aggregate number of ordinary shares reserved for issuance by 19,100,000 shares.
-
Auditor Ratified
Ernst & Young LLP was ratified as the Company's independent auditor for the fiscal year ending December 31, 2026.
-
Directors Re-elected
Robin Meng, Corazon D. Sanders, Li Mao, and Peter Salovey were re-elected as Class III directors for three-year terms.
-
Voting Participation
Approximately 330,199,682 ordinary shares, representing 84.9% of the 388,976,826 shares outstanding as of the August 17, 2026 record date, were present in person or by proxy.
Analysis · LEGN · Life Sciences
Shareholders approved a 19.1 million share increase to the 2020 Restricted Shares Plan, expanding the equity pool available for future grants. The ratification of Ernst & Young as independent auditor for fiscal 2026 is a first-disclosed governance event. The equity plan increase was previously proposed in the August 18 proxy, but the shareholder approval and the auditor ratification are new material facts.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1020 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LEGN was trading at $19.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $16.24 to $37.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.